Amy E. DeZern

TL;DR: Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event.

TL;DR: Paroxysmal nocturnal haemoglobinuria (PNH) is a clonal haematopoietic stem cell (HSC) disease that presents with haemolytic anaemia, thrombosis and smooth muscle dystonias, as well as bone marrow failure in some cases.

TL;DR: This analysis demonstrates that the DRI effectively risk stratifies recipients of NMA HLA-haploidentical BMT with PTCy and suggests that this transplantation platform yields similar survivals to those seen with HLA -matched BMT.

TL;DR: This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches for myelodysplastic syndromes.

TL;DR: The Eprenetapopt (APR-246) is a novel, first-in-class, hypomethylating agent for TP53-mutant myelodysplastic syndromes (MDS) as mentioned in this paper.